<DOC>
	<DOCNO>NCT01189019</DOCNO>
	<brief_summary>In fifth year anti-VEGF therapy neovascular AMD , retinal physician collect group patient either partially respond anti-VEGF therapy . This study evaluate efficacy safety 2mg ranibizumab specifically patient fibrovascular PEDs resolve follow least 6 consecutive injection ranibizumab bevacizumab previous 12 month . The investigator hypothesize 2mg dose able completely eliminate persistent PEDS patient .</brief_summary>
	<brief_title>HiPED - High Dose Lucentis Persistent Pigment Epithelial Detachments Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 50 year Active recurrent neovascular agerelated macular degeneration involve fovea FA Presence persistent fibrovascular pigment epithelial detachment OCT follow minimum 6 previous treatment previous 12 month ranibizumab and/or bevacizumab . Patients may receive 12 month antiVEGF therapy . ETDRS Best Corrected Visual acuity 20/32 20/400 Prior treatment verteporfin , externalbeam radiation therapy , transpupillary thermotherapy , Previous subfoveal focal laser photocoagulation involve foveal center , History vitrectomy , submacular surgery , surgical intervention AMD , Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral ) study eye . Lesion Characteristics : Subfoveal fibrosis atrophy study eye , CNV either eye due cause , ocular histoplasmosis , trauma , pathologic myopia . Concurrent Ocular Conditions : Concurrent eye disease study eye could compromise visual acuity ( e.g. , diabetic retinopathy , advanced glaucoma ) , Any concurrent intraocular condition study eye ( e.g. , diabetic retinopathy glaucoma ) , opinion investigator , could either , Require medical surgical intervention 12month study period prevent treat visual loss might result condition , If allow progress untreated , could likely contribute loss least 2 Snellen equivalent line best correct visual acuity 12month study period , Active intraocular inflammation ( grade trace ) study eye , history idiopathic autoimmuneassociated uveitis either eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Aphakia absence posterior capsule study eye unless occurred result YAG posterior capsulotomy association prior , posterior chamber intraocular lens implantation . Uncontrolled glaucoma study eye ( defined intraocular pressure 30 mmHg despite treatment antiglaucoma medication ) Concurrent Systemic Conditions Pregnancy premenopausal woman use adequate contraception The following consider effective mean contraception : surgical sterilization ; use oral contraceptive ; barrier contraception either condom diaphragm conjunction spermicidal gel ; IUD ; contraceptive hormone implant patch . History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Other Inability dilate pupil sufficient adequate fluorescein angiography Inability comply study follow procedure Subjects meet follow criterion exclude study : Pregnancy ( positive pregnancy test ) Any condition investigator believe would pose significant hazard subject investigational therapy initiate</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ranibizumab</keyword>
	<keyword>Wet macular degeneration</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>PED</keyword>
	<keyword>Retinal Pigment Epithelial Detachment</keyword>
</DOC>